Holen Sie sich die Stockscreener-App
155.46
1.83%
2.80
Handel nachbörslich:
154.64
-0.82
-0.53%
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories Hits Day Low of $151.91 Amid Price Pressure - Markets Mojo
Are Charles River’s New Advanced Therapy Deals Quietly Rewriting Its Drug-Development Moat Story (CRL)? - simplywall.st
Charles River announces strategic review including 'examination of various alternatives' - MSN
Charles River Laboratories (CRL) slides 9.6% as investors refocus on restructuring, mixed 2026 outlook, and overhang risks - Quiver Quantitative
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Charles River Labs Stock: Strong Performance vs. Underlying Business ChallengesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Zacks Research Has Optimistic Outlook of CRL Q2 Earnings - MarketBeat
Mackenzie Financial Corp Decreases Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Stock Position Lifted by Magnetar Financial LLC - MarketBeat
Natixis Advisors LLC Acquires 20,050 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Barclays PLC Reduces Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit - Yahoo Finance
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
[Latest] Global Pharmaceutical Microbiology QC Testing Market Size/Share Worth USD 17.65 Billion by 2035 at a 13.27% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis) - GlobeNewswire Inc.
CRL: Biotech demand is recovering, tech investments continue, and acquisitions strengthen core focus - TradingView
CRL: Biotech demand rebounds, portfolio streamlined, and China’s innovation eyed for future growth - TradingView
Charles River Laboratories International (CRL) Gains on Strong Results and Resilient Drug Outsourcing Demand - Yahoo Finance
A Look At Charles River Laboratories (CRL) Valuation After 2026 Guidance Cut And Planned Divestitures - Yahoo Finance
Dimensional Fund Advisors LP Purchases 120,207 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
A Look Back at Drug Development Inputs & Services Stocks' Q4 Earnings: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Pack - Finviz
How Investors Are Reacting To Charles River Laboratories (CRL) Cutting 2026 Guidance After Planned Divestitures - Yahoo Finance
GW&K Investment Management LLC Increases Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Why Charles River Laboratories International Inc. stock is upgraded to buy2025 Sector Review & AI Enhanced Trading Alerts - Naître et grandir
Quantbot Technologies LP Invests $1.44 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International (CRL) Faces Biotech R&D Spending Headwinds - Insider Monkey
Picton Mahoney Asset Management Boosts Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
LaPlume buys Charles River Labs [CRL] shares worth $4363 - Investing.com India
How Charles River Laboratories International Inc. (CRL) Affects Rotational Strategy Timing - Stock Traders Daily
Risk Hedge: Is Charles River Laboratories International Inc a potential multi baggerTrade Exit Summary & Safe Capital Preservation Plans - baoquankhu1.vn
Charles River Laboratories: Why Wall Street Suddenly Cares About This Quiet Biotech Powerhouse - AD HOC NEWS
Insider Buying: Joseph Laplume Acquires Shares in Charles River Laboratories International Inc (CRL) - GuruFocus
Charles River (NYSE: CRL) CEO receives 16,796-share stock-based award - Stock Titan
Charles River (NYSE: CRL) EVP adds 25 shares in open-market buy - Stock Titan
Charles River Laboratories: Is Wall Street Underpricing This Quiet Biotech Enabler? - AD HOC NEWS
Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working? - simplywall.st
Charles River Laboratories International, Inc. $CRL Shares Sold by Citigroup Inc. - MarketBeat
Assessing Charles River Laboratories (CRL) Valuation After Recent Mixed Share Price Performance - simplywall.st
Charles River expands footprint at Heriot-Watt University Research Park - Heriot-Watt University
Charles River Labs to outline strategy at TD Cowen and Barclays events - Stock Titan
Charles River Laboratories (CRL) Stock Analysis: Navigating the Healthcare Research Sector with 10.48% Upside Potential - DirectorsTalk Interviews
Charles River Laboratories Experiences Evaluation Revision Amidst Mixed Market Indicators - Markets Mojo
Could Cash Machine Charles River Laboratories International Stock Be Your Next Buy? - Trefis
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories parts ways with its CDMO business - European Pharmaceutical Review
Charles River Laboratories International, Inc. $CRL Stock Holdings Increased by JPMorgan Chase & Co. - MarketBeat
Charles River Laboratories to divest a number of assets to IQVIA and GI Partners - Business Weekly
IQVIA to acquire Charles River drug discovery assets - Yahoo Finance
Charles River to sell CDMO and European discovery assets By Investing.com - Investing.com Australia
Charles River Laboratories Experiences Revision in Its Stock Evaluation Amid Mixed Financial Indicators - Markets Mojo
UBS Group Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price - MarketBeat
Activist investor prompts sale of Charles River CDMO business, U.S. and European sites - The Business Journals
IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE - marketscreener.com
Charles River Laboratories (CRL) Announces Strategic Divestitures to Streamline Operations - GuruFocus
UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating - marketscreener.com
Sector Update: Health Care - marketscreener.com
Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans - Benzinga
Charles River announces divestitures, updates guidance - MSN
Charles River to sell CDMO and European discovery assets - Investing.com
Charles River Laboratories stock rises on divestiture plans By Investing.com - Investing.com Australia
IQVIA to acquire drug discovery assets from Charles River Labs - Investing.com
Charles River Laboratories to divest CDMO, Cell Solutions, and European assets - Investing.com Australia
Charles River Laboratories to Sell Certain European Assets, Businesses; Full-Year 2026 Guidance Updated - marketscreener.com
Iqvia to Acquire Discovery Services from Charles River Laborator - GuruFocus
Charles River Laboratories (CRL) to Divest European Assets for $145M - GuruFocus
0.34%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):